This change was primarily driven by a $1.9 million increase in compensation expenses, mainly as a result of increased headcount, a $0.5 million increase in non-cash stock-based compensation expense, a $0.3 million increase in marketing and advertising expenses associated with the commercialization of Barro Stem in the U.S., and a $0.1 million increase in travel expenses.

Oct 26, 2023 / CFO / receipt, needs a key / Jared Oshheim, CFO | earnings call 2023-10-26 | transcript fb077014-5e92-465b-8da7-0f6638ed5168 | chars 8024-8397 | segment 8